30.09.2024
Akeso’s Ebronucimab(PCSK9) Approved for Two Indications for the Treatment of Hypercholesterolemia in China
30.09.2024
Akeso's Cadonilimab Receives Second Indication Approval from NMPA for First-Line Treatment of Gastric/GEJ Cancer in All-Comers Population
18.09.2024
ESMO 2024 | Akeso Published Ivonescimab plus Ligufalimab as First-Line Treatment for PD-L1–Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Who We Are?
A pioneer in developing innovative antibodies

Akeso, Inc. (HKEX Code: 9926. HK) is a biopharmaceutical company founded by a team of scientists with rich experience in global drug development and focuses on the unmet clinical needs worldwide in major diseases. The Company has created a unique integrated R&D innovation system with a comprehensive end-to-end drug development platform (ACE Platform) and bi-specific antibody drug development technology (Tetrabody) ,ADC technology ,mRNA technology and? the cell therapy technology as the core, a GMP-compliant manufacturing system, and a commercialization system with an advanced operation mode.?

Through efficient and breakthrough R&D innovation, Akeso always integrates superior global resources, develops the first-in-class and best-in-class new drugs, provides affordable therapeutic antibodies for patients worldwide, and continuously creates more commercial and social values so as to become a leading global biopharmaceutical enterprise.

Collaborations
Foreign cooperation

If you have any products or opportunities to cooperate and develop with us

Summit白字logo 50Px高 logo图层 0 (4) logo图层 3 (1) logo图层 4 (1) logo图层 1 (1) logo图层 2 (1) logo
Pipelines
Product pipeline

We have One of the richest and most diversified innovative antibody drug pipeline in China

组 6 (2) logo